全文获取类型
收费全文 | 40383篇 |
免费 | 10172篇 |
国内免费 | 1587篇 |
专业分类
耳鼻咽喉 | 585篇 |
儿科学 | 1011篇 |
妇产科学 | 984篇 |
基础医学 | 5918篇 |
口腔科学 | 832篇 |
临床医学 | 4265篇 |
内科学 | 8001篇 |
皮肤病学 | 1064篇 |
神经病学 | 3078篇 |
特种医学 | 2454篇 |
外国民族医学 | 3篇 |
外科学 | 6832篇 |
综合类 | 1117篇 |
一般理论 | 7篇 |
预防医学 | 2166篇 |
眼科学 | 1339篇 |
药学 | 3727篇 |
中国医学 | 542篇 |
肿瘤学 | 8217篇 |
出版年
2023年 | 967篇 |
2022年 | 1894篇 |
2021年 | 2060篇 |
2020年 | 1768篇 |
2019年 | 1846篇 |
2018年 | 3342篇 |
2017年 | 2135篇 |
2016年 | 1765篇 |
2015年 | 1982篇 |
2014年 | 1648篇 |
2013年 | 2133篇 |
2012年 | 2825篇 |
2011年 | 2665篇 |
2010年 | 1752篇 |
2009年 | 1545篇 |
2008年 | 2165篇 |
2007年 | 2091篇 |
2006年 | 2068篇 |
2005年 | 1818篇 |
2004年 | 1666篇 |
2003年 | 1333篇 |
2002年 | 1157篇 |
2001年 | 925篇 |
2000年 | 783篇 |
1999年 | 925篇 |
1998年 | 450篇 |
1997年 | 348篇 |
1996年 | 1006篇 |
1995年 | 398篇 |
1994年 | 388篇 |
1993年 | 185篇 |
1992年 | 297篇 |
1991年 | 351篇 |
1990年 | 233篇 |
1989年 | 244篇 |
1988年 | 209篇 |
1987年 | 195篇 |
1986年 | 194篇 |
1985年 | 186篇 |
1984年 | 124篇 |
1983年 | 116篇 |
1979年 | 146篇 |
1977年 | 110篇 |
1975年 | 122篇 |
1974年 | 126篇 |
1973年 | 136篇 |
1972年 | 125篇 |
1971年 | 129篇 |
1970年 | 108篇 |
1969年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 11 毫秒
1.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
2.
Proteomic Profiling of Small Extracellular Vesicles Isolated from the Plasma of Vietnamese Patients with Non-Small Cell Lung Cancer Reveals Some Potential Biomarkers 下载免费PDF全文
Thao Phuong Bui Phuong Lan LeLinh Thi Tu Nguyen Le Trung ThoThai Hong Trinh 《Asian Pacific journal of cancer prevention》2022,23(6):1893-1900
Background: Considering the poor prognosis of non-small cell lung cancer (NSCLC), the objective of this study was to examine the potential of plasma-derived vesicles as a source of lung cancer-specific proteins. Extracellular vesicle (EV) cargos are specific to the source cells, hence they have the potential of being a source of cancer-specific proteins. Methods: The proteins differently expressed in cancer were determined and derived from EVs isolated from the plasma of NSCLC patients at the National Lung Hospital. To this end, purification was done using gel filtration chromatography and ultracentrifugation. In addition, nano liquid chromatography mass spectrometry (LC–MS/MS) was used for analyzing. Results: Fifty-seven EV-derived proteins related to NSCLC were highlighted in this research. Some of them have not been addressed before, such as EEF1A1 (elongation factor 1-α1), KPNB1 (Importin subunit beta 1), SRC (proto-oncogene tyrosine-protein kinase) and ACTC1 (actin, alpha cardiac muscle 1). This list was further confirmed through a comparison with ExoCarta and Vesiclepedia. Conclusion: This study is the first work to show the involvement of several novel proteins of small EV (EEF1A1, KPNB1, SRC, and ACTC1) in the progression of NSCLC. The results suggested that they could serve as novel biomarkers for non-small cell lung cancer in the future. 相似文献
3.
4.
目的 了解国内三家医院临床确诊隐球菌病的分布、药敏试验、临床特点以及抗生素治疗等,提高临床对隐球菌病临床特征的认识。方法 回顾性分析2018 ~ 2019 年国内三家医疗机构33 例确诊隐球菌病患者的临床表现、治疗、预后及实验室检查和药敏结果。结果 33 例隐球菌病患者(男性25 例,女性8 例)平均年龄50.4±12.6 岁,10 例无基础疾病。33 株隐球菌中新生隐球菌31 株,格特隐球菌2 株,其中16 株(48.5%) 来自脑脊液,7 株(21.2%) 来自肺穿组织。常见的中枢神经系统的临床症状有发热18 例,头痛14 例,恶心呕吐9 例。药敏结果显示,所有菌株对两性霉素B、氟康唑、伊曲康唑和伏立康唑均没有获得耐药;1 株对氟胞嘧啶有获得性耐药。脑隐球菌病主要选择两性霉素B 进行治疗,肺隐球菌病选择氟康唑,好转15 例,死亡3 例,转院8 例,另有7 例未经治疗转院。结论 隐球菌对人类致病的主要是新生隐球菌和格特隐球菌。中枢神经系统症状以发热、头痛和恶心呕吐最常见,单纯肺隐球菌病无典型的中枢神经系统的症状;绝大多数菌株均没有获得耐药;临床应重视病原学检测,及时使用抗真菌治疗,对疾病的诊治和预后十分重要。 相似文献
5.
6.
Maxime Lafond Shin Yoshizawa Shin‐ichiro Umemura 《Journal of ultrasound in medicine》2019,38(3):567-580
Sonodynamic therapy (SDT) consists of the synergetic interaction between ultrasound and a chemical agent. In SDT, the cytotoxicity is triggered by ultrasonic stimuli, notably through cavitation. The unique features of SDT are relevant in the clinical context more than ever: the need for efficacy, accuracy, and safety while being noninvasive and preserving the patient's quality of life. However, despite the promising results of this technique, only a few clinical reports describe the use of SDT. The objective of this article is to provide an extensive overview of the clinical and preclinical research conducted in vivo on SDT, to identify the limitations, and to detail the developed strategies to overcome them. 相似文献
7.
8.
Cheong-Il Shin Sang Joon Park Ji-Hyun Kim Yeonyee Elizabeth Yoon Eun-Ah Park Bon-Kwon Koo Whal Lee 《Korean journal of radiology》2021,22(5):688
ObjectiveTo compare the lumen parameters measured by the location-adaptive threshold method (LATM), in which the inter- and intra-scan attenuation variabilities of coronary computed tomographic angiography (CCTA) were corrected, and the scan-adaptive threshold method (SATM), in which only the inter-scan variability was corrected, with the reference standard measurement by intravascular ultrasonography (IVUS).Materials and MethodsThe Hounsfield unit (HU) values of whole voxels and the centerline in each of the cross-sections of the 22 target coronary artery segments were obtained from 15 patients between March 2009 and June 2010, in addition to the corresponding voxel size. Lumen volume was calculated mathematically as the voxel volume multiplied by the number of voxels with HU within a given range, defined as the lumen for each method, and compared with the IVUS-derived reference standard. Subgroup analysis of the lumen area was performed to investigate the effect of lumen size on the studied methods. Bland-Altman plots were used to evaluate the agreement between the measurements.ResultsLumen volumes measured by SATM was significantly smaller than that measured by IVUS (mean difference, 14.6 mm3; 95% confidence interval [CI], 4.9–24.3 mm3); the lumen volumes measured by LATM and IVUS were not significantly different (mean difference, −0.7 mm3; 95% CI, −9.1–7.7 mm3). The lumen area measured by SATM was significantly smaller than that measured by LATM in the smaller lumen area group (mean of difference, 1.07 mm2; 95% CI, 0.89–1.25 mm2) but not in the larger lumen area group (mean of difference, −0.07 mm2; 95% CI, −0.22–0.08 mm2). In the smaller lumen group, the mean difference was lower in the Bland-Altman plot of IVUS and LATM (0.46 mm2; 95% CI, 0.27–0.65 mm2) than in that of IVUS and SATM (1.53 mm2; 95% CI, 1.27–1.79 mm2).ConclusionSATM underestimated the lumen parameters for computed lumen segmentation in CCTA, and this may be overcome by using LATM. 相似文献
9.
10.
Gynecologic Malignancy-Associated Venous Thromboembolism and Predictive Tool at Thammasat University Hospital 下载免费PDF全文
Karit JayasakoonAwassada PunyashthiraBanthisa SomboonJunya PattaraarchachaiKomsun Suwannarurk 《Asian Pacific journal of cancer prevention》2022,23(6):2113-2118
Objectives: Aims were to investigate the prevalence and risk factors of venous thromboembolism (VTE) in gynecologic malignancy cases. Value of screening tool (Caprini) for prediction of VTE was also assessed. Study design: A retrospective study of gynecologic malignancy subjects who underwent major gynecological operation via exploratory laparotomy at Thammasat University Hospital, Pathum Thani, Thailand from January 2015 to December 2020. Participants were categorized into VTE and non-VTE groups. Caprini score, associated laboratory and clinical factors of both groups were evaluated. Results: A total of 392 subjects were recruited into the study. Prevalence of VTE was 7.4 (29/392) percent. VTE was diagnosed in subjects with endometrial, ovarian and cervical cancer at percentage of 7.8 (15/192), 7.9 (11/138) and 5.7 (3/53), respectively. Demographic characters of both groups were comparable. VTE group had significant more Caprini score, platelets count and platelet lymphocyte ratio (PLR) than non-VTE group. Modified Caprini score (2 multiply Caprini score plus 1 multiply PLR) was generated for better VTE prediction. Sensitivity and specificity of Caprini (≥5.5) and modified Caprini scores (≥22.8) were 72.4 vs 39.4, and 79.3 vs 52.1 percent, respectively. Conclusion: Prevalence of VTE among gynecologic malignancy cases was 7.4 percent. The modified Caprini score was an alternative VTE predictive tool. Cut-off point of modified Caprini score at equal or more than 22.8 was proposed. 相似文献